Cargando…
Evaluation of dosing strategy for pembrolizumab for oncology indications
BACKGROUND: Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies; however, following availability of PK data, the need for w...
Autores principales: | Freshwater, Tomoko, Kondic, Anna, Ahamadi, Malidi, Li, Claire H., de Greef, Rik, de Alwis, Dinesh, Stone, Julie A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433037/ https://www.ncbi.nlm.nih.gov/pubmed/28515943 http://dx.doi.org/10.1186/s40425-017-0242-5 |
Ejemplares similares
-
Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016) -
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma
por: Chatterjee, MS, et al.
Publicado: (2016) -
Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019) -
Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma
por: de Greef, R, et al.
Publicado: (2016) -
Dose Finding in Oncology: What is Impeding Coming of Age?
por: Mayawala, Kapil, et al.
Publicado: (2022)